Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
China NT Pharma Group Co., Ltd. ( (HK:1011) ) has issued an announcement.
China NT Pharma Group reported audited annual results for the year ended 31 December 2025, showing revenue of RMB24.16 million, down from RMB37.96 million a year earlier, but an improved gross profit of RMB9.61 million versus RMB5.26 million in 2024. The group’s loss for the year narrowed to RMB26.26 million from RMB53.36 million, aided by lower administrative expenses and positive fair value changes on financial assets.
Finance costs remained heavy at RMB27.84 million, continuing to weigh on profitability, while the absence of prior-year one-off losses related to deconsolidation of subsidiaries and associate revaluation also supported the reduced loss. Despite the net loss, total comprehensive loss was nearly breakeven at RMB0.51 million, helped by significant positive exchange differences, suggesting some stabilization in the group’s overall financial position.
The most recent analyst rating on (HK:1011) stock is a Hold with a HK$0.76 price target. To see the full list of analyst forecasts on China NT Pharma Group Co., Ltd. stock, see the HK:1011 Stock Forecast page.
More about China NT Pharma Group Co., Ltd.
China NT Pharma Group Co., Ltd. is a Hong Kong-listed pharmaceutical group engaged in healthcare-related services and investments. The company operates through subsidiaries and associates, focusing on generating revenue from service income and financial assets within the pharmaceutical and healthcare sector in mainland China and related markets.
Average Trading Volume: 281,244
Technical Sentiment Signal: Hold
Current Market Cap: HK$683.3M
For detailed information about 1011 stock, go to TipRanks’ Stock Analysis page.